ATE126061T1 - Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum. - Google Patents

Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.

Info

Publication number
ATE126061T1
ATE126061T1 AT91309994T AT91309994T ATE126061T1 AT E126061 T1 ATE126061 T1 AT E126061T1 AT 91309994 T AT91309994 T AT 91309994T AT 91309994 T AT91309994 T AT 91309994T AT E126061 T1 ATE126061 T1 AT E126061T1
Authority
AT
Austria
Prior art keywords
prophylaxis
treatment
lithium
molluscum
lithium compound
Prior art date
Application number
AT91309994T
Other languages
English (en)
Inventor
David Frederick Horrobin
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Application granted granted Critical
Publication of ATE126061T1 publication Critical patent/ATE126061T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT91309994T 1990-10-31 1991-10-30 Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum. ATE126061T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909023701A GB9023701D0 (en) 1990-10-31 1990-10-31 Medical treatment

Publications (1)

Publication Number Publication Date
ATE126061T1 true ATE126061T1 (de) 1995-08-15

Family

ID=10684665

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91309994T ATE126061T1 (de) 1990-10-31 1991-10-30 Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.

Country Status (11)

Country Link
US (1) US5223271A (de)
EP (1) EP0484112B1 (de)
JP (1) JPH06263644A (de)
AT (1) ATE126061T1 (de)
AU (1) AU645359B2 (de)
CA (1) CA2052246A1 (de)
DE (1) DE69111974T2 (de)
DK (1) DK0484112T3 (de)
GB (1) GB9023701D0 (de)
GR (1) GR3017855T3 (de)
IE (1) IE71171B1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756107A (en) * 1994-12-21 1998-05-26 Cosmederm Technologies Formulations and methods for reducing skin irritation
US7404967B2 (en) 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
US5840711A (en) * 1995-06-21 1998-11-24 University Of Kentucky Research Foundation Compositions containing lithium inorganic salts and anti-viral drugs and method of treating viral infections such as acquired immunodeficiency syndrome
DE69838485T2 (de) * 1997-10-09 2008-06-26 Emory University Verfahren und vorrichtung zur transdermalen verabreichung von lithium
FR2783424B1 (fr) * 1998-09-03 2002-10-04 Labcatal Utilisation du gluconate de lithium dans la fabrication d'un medicament pour le traitement de l'herpes et de la dermite seborrheique
WO2001049300A2 (en) * 1999-12-30 2001-07-12 Henderson Morley Research And Development Limited Combinations for the treatment of dna viral infections comprising a loop diuretic and lithium
ES2164018B1 (es) * 2000-05-26 2003-06-16 Inst De Salud Carlos Iii Empleo de una sal de litio en la elaboracion de un medicamento para el tratamiento de la infeccion causada por el virus respiratorio sincitial humano (vrdh)
US7311928B2 (en) * 2003-12-09 2007-12-25 Briant Burke Topical compositions containing tea tree oil for treatment of viral lesions
EP2143421A1 (de) * 2008-07-07 2010-01-13 Almirall Hermal GmbH Zusammensetzung zur topischen Behandlung von Strahlenkeratose
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012125941A1 (en) * 2011-03-17 2012-09-20 Follica, Inc. Lithium treatment for microbial infections
HK1222337A1 (zh) * 2013-05-03 2017-06-30 Emollivet Ab 用於施加药物活性成分或化妆品活性成分的局部组合物和载体
EP4034136A4 (de) * 2019-06-19 2023-07-05 The United States Government As Represented By The Department Of Veterans Affairs Formulierungen mit lithium zur behandlung von gichtarthropathie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639625A (en) * 1967-07-13 1972-02-01 Lewis Sherwin Compositions containing lithium succinate
US4396452A (en) 1978-12-21 1983-08-02 Monsanto Company Process for point-bonding organic fibers
JPS5590505A (en) 1978-12-29 1980-07-09 Kureha Chem Ind Co Ltd Carboxyalkylchitin and preparation of deacetylated product thereof
US4328243A (en) * 1981-04-07 1982-05-04 Horrobin David F Manic-depressive illnesses
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
AU556817B2 (en) * 1982-02-03 1986-11-20 Efamol Limited Topical application of a lithium salt and dihomo-alpha- linolenic acid
GB8318912D0 (en) * 1983-07-13 1983-08-17 Horrobin D F Compositions for treatment of skin/hair
GB8320203D0 (en) * 1983-07-27 1983-09-01 Horrobin D F Anti-viral compositions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
EP0289204B1 (de) * 1987-04-27 1991-07-17 Efamol Holdings Plc Lithiumsalze enthaltende pharmazeutische Zubereitungen
GB8719988D0 (en) * 1987-08-25 1987-09-30 Efamol Ltd Chemical compounds

Also Published As

Publication number Publication date
EP0484112B1 (de) 1995-08-09
DE69111974D1 (de) 1995-09-14
AU8687391A (en) 1992-05-07
EP0484112A3 (en) 1992-07-08
AU645359B2 (en) 1994-01-13
IE913787A1 (en) 1992-05-22
GB9023701D0 (en) 1990-12-12
JPH06263644A (ja) 1994-09-20
US5223271A (en) 1993-06-29
EP0484112A2 (de) 1992-05-06
DK0484112T3 (da) 1995-09-18
CA2052246A1 (en) 1992-05-01
GR3017855T3 (en) 1996-01-31
DE69111974T2 (de) 1996-01-04
IE71171B1 (en) 1997-01-29

Similar Documents

Publication Publication Date Title
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
LV10180A (lv) Farmaceitiska kompozicija
DE3382458D1 (de) Haarwuchsmittel.
MX9203543A (es) Medicamento.
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
ATE100320T1 (de) Verwendung von thromboxan-a2-rezeptorantagonisten zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von hautkrankheiten.
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
ATE187642T1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
ATE220912T1 (de) Herstellung von st1435 enthaltenden pharmazeutischen zusammensetzungen zur topischen verwendung
DK347289D0 (da) Terapeutiske forbindelser
MY104521A (en) Treatment of depression.
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
ATE78160T1 (de) Verwendung von ''naftidrofuryl'' zur behandlung von neuropathien.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee